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Enhancement by factor V Leiden mutation of risk of deep-vein
thrombosis associated with oral contraceptives containing a
third-generation progestagen
Kitty W M Bloemenkamp, Frits R Rosendaal, Frans M Heimerhorst, Harry R Büller, Jan P Vandenbroucke
Summary
Recent concern about the safety of combined oral
contraceptives (OCs) with third-generation progestagens
prompted an examination of data from a population-based
case-control study (Leiden Thrombophilia Study). We
compared the risk of deep-vein thrombosis (DVT) during
use of the newest OCs, containing a third-generation
progestagen, with the risk of "older" products. We also
investigated the influence of family history of thrombosis,
previous pregnancy, age, and the thrombogenic factor V
Leiden mutation.
We selected 126 women with DVT and 159 controls
aged 15-49 (mean age 34-9) and premenopausal and
found, äs compared with non-users, the highest age-
adjusted relative risks to be that for an OC containing
desogestrel and 30 μg ethinyloestradiol (relative risk [RR]
8-7, 95% Cl 3-9-19-3). We found Iower relative risks for all
other types of OC, ranging from 2-2 to 3-8. In a direct
comparison, users of the desogestrel-containing oral
contraceptive had a 2-5-fold higher risk (95% Cl 1-2-5-2)
than users of all other OC types combined. The relative risk
for the desogestrel-containing OC was similar among
women with and without a family history—ie, preferential
prescription because of family history cannot explain our
findings. Nor could the excess risk be explained by
previous pregnancy, and it was highest in the youngest age
categories, where we would expect most new users. The
age-adjusted RR for the desogestrel-containing
contraceptive was 9-2 (3-9-21-4) among non-carriers of
the factor V Leiden mutation and 6-0 (1-9-19-0) among
carriers of the mutation. This latter risk is superimposed on
the 8-fold increased risk of venous thrombosis for carriers
Department of Obstetrics, Gynaecology, and Reproductive
Medlclne (K W M Bloemenkamp MD, F M Heimerhorst MD),
Department of Cllnlcal Epidemlology (F R Rosendaal MD,
Prof J P Vandenbroucke MD), and Thrombosis and Haemostasis
Research Centre (F R Rosendaal) Unlversity Hospital Leiden,
Leiden; and Centre for Haemostasis, Thrombosis,
Atherosclerosis, and Inflammation Research (H R Büller MD),
Academlc Medlcal Centre of University of Amsterdam, Netherlands
Correspondence to: Dr Frits R Rosendaal, Department of Clinical
Epidemiology, Leiden University Hospital, Building 1-CO-P,
PO Box 9600, 2300 RC Leiden, Netherlands
of the factor V Leiden mutation. The risk of carriers using
the desogestrel-containing OC äs compared with non-
carrier non-users will therefore be increased almost 50-fold.
Use of Iow-dose OCs with a third-generation progestagen
carries a higher risk of DVT than the previous generation of
OCs. The absolute risk of DVT associated with these OCs
seems to be especially high among carriers of the factor V
Leiden mutation and among women with a family history of
thrombosis. However, the higher risk associated with OC
with a third-generation progestagen compared with
previous generations was also present in women without
factor V Leiden and with no family history.
Lancet 1995; 346:1593-96
See Editorial page 1569 and Commentary page 1570
Introduction
Since the early 1960s it has been known that oral
contraceptives (OC) increase the risk of venous and
arterial thrombosis. Efforts to reduce the risk by
decreasing the oestrogen content have proved
successful." Third-generation progestagens were
introduced in an attempt to Iower further the risk of
cardiovascular side-effects. These new progestagens
include desogestrel, gestodene, and norgestimate.5'6 Since
these progestagens had less androgenic metabolic effects
and did not adversely affect the lipid profile, it was
thought that they might carry a Iower risk of
cardiovascular diseases than older progestagens such äs
levonorgestrel, lynoestrenol, and norethisterone.5·7
There is no evidence yet from studies with clinical
endpoints that these new progestagens do reduce the risk
of cardiovascular diseases. Most studies of combined OCs
containing the new progestagens have been small
comparative trials on Surrogate endpoints such äs
coagulation pattern and fibrinolytic and lipid levels in
healthy young women.5·7
Uncertainty about the safety of the newest Iow-dose
OCs prompted us to reanalyse data'from a case-control
study. We focused on the possibility that OCs with a low
dose of ethinyloestradiol and a third-generation
progestagen would carry a greater risk of venous
thrombosis than OCs containing similar doses of
ethinyloestradiol but other progestagens. We also looked
for alternative explanations, by investigating the effect of a
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positive family history of venous thrombosis, a history of
pregnancy, and age. A positive family history of deep-vein
thrombosis (DVT) might lead to a preferential
prescription of a new low-dose OC. Women who have
ever been pregnant have been exposed to higher oestrogen
levels and might differ in other aspects from those who
were never pregnant. Duration of use may also be a factor
so we did an analysis among the youngest women, most of
whom will be new users.
Factor V Leiden mutation, which leads to resistance to
activated protein C and is commonly found among
patients with venous thrombosis (20% carriers), displays a
strong interaction with use of OCs, all types combined. In
non-carriers who use OCs the risk of thrombosis is
increased 4-fold, but the risk rises to 30-50 fold in users
of OCs who also carry the factor V Leiden mutation.8
Patients and methods
The patients and methods have been described previously.8·' We
invited 474 consecutive patients (both sexes) with a first episode
of proven DVT, diagnosed objectively between Jan l, 1988 and
Dec 31, 1992, who were aged less than 70 and who were not
known to have malignant disorders. Patients had been selected
from the files of three anticoagulation clinics in the Netherlands,
which monitor anticoagulant treatment in all patients within a
well-defined geographical area. For each thrombosis patient we
invited one age and sex matched healthy control.
For the present analysis we selected only premenopausal
women, aged 15-49 (mean age: 34-9), who were at the time of
their thrombosis (or similar date for a control) not pregnant, nor
in the puerperium, had not had a recent miscarriage, and had not
used injectable progestagens."
Information on the type of OCs used at the time of the
thrombosis (or index date in the control) was obtamed from the
interview supplemented with data from the hospital discharge
letter. This led to complete Information on OC type in 95% of
the 174 users.
We limited the analysis to types of OCs for which sufficient
cases and controls were available (ie, 5 or more case and
controls). We left out of the analysis a total of 20 cases and 10
controls who used the following preparations: monophasic 30 μg
ethinyloestradiol and gestodene, 50 μg mestranol and
norethisterone, 35 μ§ ethinyloestradiol and cyproterone acetate,
biphasic ethinyloestradiol and desogestrel, and ethinyloestradiol
and lynoestrenol. We also discarded data from 9 women (cases)
in whom the type of OC remamed unknown. Thus 29 cases and
10 controls were left out of the analysis.
Because the choice of OC might have been mfluenced by the
perception of an increased risk known through a family history of
venous thrombosis, we took family history into account. We
called a family history "positive" when venous thrombosis was
reported in one or more parents or siblings by the patient or
control.
Presence of the mutant factor V Leiden gene was determined10
by technicians who did not know if the sample was from a patient
or a control or from an OC user or non-user.
We analysed data from 285 women (126 cases and 159
controls) on current use of OCs at their thrombosis or index
date. The OC types were classed äs: (1) monophasic, containing
30 μg ethinyloestradiol and 150 μg desogestrel; (2) monophasic,
containing 30 μg ethinyloestradiol and 150 μg levonorgestrel; (3)
monophasic, containing 50 μg ethinyloestradiol and 125 μg or
250 μg levonorgestrel or 1000 μg lynoestrenol; (4) triphasic,
containing ethinyloestradiol and levonorgestrel or norethisterone;
or (5) monophasic, containing 35 μg or 37-5 μg ethinyloestradiol
and 1000 μg norethisterone or 750 μg lynoestrenol.
To assess the risk of different types of OC among factor V
Leiden positive and negative cases, we used the complete control
group äs a reference for frequency of OC use, because at the time
diese contraceptives had been prescribed for the women in our
study factor V Leiden was unknown. The complete control
Type of OC Cases/controls RR
Amount of
ethinyloestradiol
30 μg
30u,g
50 |ig
Triphasic
(30-40 (ig)
35 μg
375μ|
No OCs
Type of progestagen
Desogestrel
Levonorgestrel
Levonorgestrel or
lynoestrenol
Levonorgestrel or
norethisterone
Norethisterone
Lynoestrenol
37/15
20/18
8/6
7/11
8/5
46/104
8 7 (3-9-19 3)
38(1-7-84)
3-4(11-10-7)
2-2 (0 8-6 5)
3-8(1-2-12-5)
10
29 cases and 10 controls usmg types of rarely used OC for which no meanmgful
analysis was possible, or for whom the type of OC used was unknown, were left out of
this analysis
Table 1: Numbers of cases and controls and age-adjusted RR
(95% Cl) for DVT according to type of OC used at time of
thrombosis
group thus represents the best estimate of the population use of
the various types of OCs.
Although the original data were age-matched we did an
unmatched analysis. Because of the inclusion criteria and the age
cut-off, many pairs were no longer intact in the database for this
analysis. Since the analysis was restricted to the matching factor
sex, we adjusted for confoundmg by the other matching factor
(age) by controlling for age by logistic regression. Age was
entered äs a continuous variable (in years); use of a categorised
dummy variable model led only to trivial differences for the
estimators of interest.
Results
Table l shows the number of cases and controls using the
various OC types and age-adjusted relative risks (RR, all
relative to non-users). The highest RR of 8-7 was for the
desogestrel-containing monophasic OC. For all other
types of OC the RR was between 2-2 and 3-8. Τοο few
women were using contraceptives containing gestodene or
norgestimate to permit meaningful conclusions. Direct
comparison of two OCs with identical oestradiol content
(30 μg ethinyloestradiol) but with a different progestagen
(ie, desogestrel vs levonorgestrel) revealed a 2-2-fold
increased risk associated with desogestrel (95% CI
0-9-5-4). When we compared the OC containing
desogestrel and 30 ^g ethinyloestradiol with all other
types combined the age-adjusted RR was 2-5 (1-2-5-2).
A family history of thrombosis was present in 41 cases
and 23 controls (RR=2-9 [1-6-5-1]), indicating a higher
baseline risk in women with a positive family history.
When we restrict the analysis to patients and controls with
a positive family history, the age-adjusted RR (vs non-
users) for the desogestrel-containing product was 7-2
(1-2-42-1) and for the levonorgestrel-containing product
it was 3-9 (0-6-24-6). For women with a negative family
history, the RRs were 8-0 (3-2-20-1) and 3-3 (1-3-8-5)
respectively.
Of the cases and controls with a positive family history
17% (11/64) carried the factor V Leiden mutation while
the mutation was found in only 8% (18/221) of cases and
controls without a family history. When we adjusted for
all these variables jointly, by entering age, factor V Leiden
mutation, and family history in a logistic model, the RRs
associated with the various OCs remained essentially the
same and the 2-fold higher risk for desogestrel persisted
when we contrasted the desogestrel-containing OC to the
levonorgestrel-containing one.
Further adjustment for history of pregnancy did not
change the estimates. Among women who have never
been pregnant RRs of 20-8 (4-8-90-2) for the desogestrel
OC and 7-7 (1-8-32-9) for the levonorgestrel product
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Type of OC
Amount of
ethmyloestradiol
30 μ.0
30 μg
50 μg
Tnphasic
(30-40 vSi
35 μg
375μg
NoOCs
Type of
progestagen
Desogestrel
Levonorgestrel
Levonorgestrel or
lynoestrenol
Levonorgestrel or
norethisterone
Norethisterone
Lynoestrenol
Gases
Factor V
positive
8
3
1
1
2
10
Factor V
negative
29
17
7
6
6
36
RR
Factor V
positive
6-0
(1-9-190)
1-9
(0 4-8 5)
18
(0-2-16 3)
10
(0 1-9-4)
41
(0-7-24-0)
1-0
Factor V
negative
92
(3 9-21 4)
4-2
1-8-9-7)
3-9
(1-2-129)
2-6
(0 8-8-0)
38
(1 1-13-6)
10
29 cases and 10 controls usmg types of rarely used OC for which no meanmgful
analysis was possible, or for whom the type of OC used was unknown, were left out of
this analysis.
Table 2: Numbers of factor V positive and factor V negative
cases and age-adjusted RR (95% Cl) for DVT with total control
group äs reference population, according to type of OC used at
time of thrombosls
(both with similar amounts of ethinyloestradiol) were
found. Among ever-pregnant women we found RRs of 5-1
(1-7-15-3) and 3-0 (1-0-9-6), respectively, compared with
non-users.
When we restricted the analysis to the youngest women,
where most new users will be found, we found the highest
risks for the desogestrel-containing OC, relative to
levonorgestrel. Among women aged 15-19 the risk of the
desogestrel-containing OC was 7-fold higher than that of
the levonorgestrel-containing product; among women
aged 20-24 the risk was 4-fold higher.
Table 2 shows age-adjusted RRs for factor V Leiden
carriers and non-carriers. We must stress that the risk of
the OC is superimposed on the baseline risk.8 The
baseline risk is much higher (8-fold) in carriers of the
factor V Leiden mutation Üian among non-carriers, so
that the RR of 6-0 (1-9-19-0) leads to a much larger
Overall effect in factor V positives than in the factor V
negatives (RR 9-2 [3-9-21-4]). The risk of carriers who
use the desogestrel-containing OC, compared with non-
carrier, non-users, will therefore be increased almost 50-
fold. Contrasting the different OC groups, we found that,
relative to 30 μg ethinyloestradiol OCs with
levonorgestrel, the newer progestagen carries a 3-5
(0-8-15-9) higher risk among factor V positives (age-
adjusted analysis) and only a 2-1 (0-8-5-3) higher risk
among factor V negatives. Table 2 shows that the
combined RR of all other types of progestagen is lower in
factor V positives.
We found no factor V Leiden positive controls who
used OCs, and 4% carriers among non-users controls.
Among the cases, the factor V Leiden mutation was
present in 22% of non-users, also in 22% of users of
desogestrel-containing OCs and in 15% of levonorgestrel
(30 μg ethinyloestradiol) containing OCs. Even though
the absence of mutant gene carriers among the users of
OCs in the controls render analysis with an interation
term in a regression model impossible, diese data again
point to a high risk associated with the combination of
factor V Leiden carriership and use of a desogestrel-
containing OC.
Discussion
We found that a new low-dose OC with a third-generation
progestagen has a higher risk of DVT than OCs with
previous generations of progestagens. This effect is
enhanced by factor V Leiden mutation and by a family
history of venous thrombosis. However, neither factor V
Leiden nor the family history explains all of the excess
risk of a third-generation progestagen, since the risk was
also increased in women without the factor V Leiden
mutation and without a family history of thrombosis.
In this study almost all of the combined OCs with
third-generation progestagens contained desogestrel. OCs
containing gestodene, norgestimate, or 20 μg
ethinyloestradiol were not or only rarely used in the
Netherlands during the time period of the investigation.
Hence, our conclusions focus on desogestrel but are not
necessarily limited to OCs containing this third-
generation progestagen.
One objection to the findings might be that the newest
OCs have been preferentially prescribed to individiuals
with the highest risk of thrombosis (confounding by
indication). This would mean that the excess risk might
be paradoxical but expected and not a consequence of the
type of OC. A factor that could lead to such preferential
prescription is a positive family history of venous
thrombosis. The excess risk was also present in women
with a negative family history, however, and a logistic
model which was adjusted for family history, factor V
Leiden mutation, and age together showed the same
relative risks for the various types of contraceptive.
Besides family history and clotting defects, there are no
generally accepted strong risk factors for DVT in healthy
young people that could lead to preferential prescription
patterns; smoking seems not a risk factor for venous
thrombosis, and obesity and varicose veins are at most a
weak risk.13''4 It therefore seems unlikely that preferential
prescribing can explain the higher risk of DVT with an
OC containing a third-generation progestagen, since
prescribers cannot readily identify women at high risk.
Because pregnancy is a risk factor for thrombosis that
might affect the same women who are "sensitive" to OCs,
and since women who have been pregnant may use
different brands of OC, we did an analysis adjusted for
previous pregnancy (ever/never). This did not change die
estimates.
A similar issue is whether pari of the observed risk
could have been brought about by differences between
women who Start oral contraception for the first time and
those who have used them for some time. Among die
youngest users (15-19 years), where most will be recent
users, we again found the excess risk for the desogestrel-
containing OC.
Our study took place within anticoagulation clinics that
serve well-defined geographical areas in the Nedierlands
where patients with thrombosis are routinely monitored,
and consecutive patients with a first objectively diagnosed
DVT were enrolled. Therefore the study itself could not
have introduced any change in referral patterns,
diagnostic methods, or treatment.
We previously reported an interaction between OC use
and factor V Leiden carriership which appeared to be
synergistic.8 Our current data show that this synergy
seems to a large part due to a positive interaction between
a desogestrel-containing OC and, factor V Leiden
mutation. The number of carriers of this mutation,
however, was small, especially among control users of
OCs, which made an analysis of the interaction in an age-
adjusted model impossible and also led to estimates with
a considerable statistical uncertainty. The meaning of the
finding is open to Interpretation: on the one hand, it
might simply imply that carriers of the mutation are at a
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higher risk when using OCs because of a multiplication of
risks. If so the factor V Leiden mutation would only
indicate a subgroup with a higher baseline risk, such äs
farnily history. On the other hand, this finding might give
a clue about the mechanism of the thrombogenic nature
of these contraceptives and should prompt further
research—first, to confirm the finding of a synergistic
effect and second to study the effect of different types of
OC on the haemostatic System, also in women without
apparent genetic abnormalities since their risk too was
increased by OCs containing a third-generation
progestagen.
When we come to look back on the history of oral
contraception it is certain that the decrease in the dose of
ethinyloestradiol will be seen to have contributed to a
reduced thrombotic risk, especially for arterial
disease.3·13·14 However, the use of a third-generation
progestagen does seem to have led to an unexpected and
yet unexplained return of a higher risk of venous
thrombosis.
We thank all the patients who took part in this study; Dr T Koster, the
investigator of the original study; Dr F J M van der Meer (Anticoagulation
Clinic Leiden), Dr L P Colly (Anticoagulation Clinic Amsterdam) and Dr
P H Trienckens (Anticoagulation Clinic Rotterdam) for their cooperation;
Mrs A van Beek for secretarial and administrative Support; Mrs T Visser
for laboratory assistance; and Air P A van der Velden for DNA analysis.
The original study was funded by the Netherlands Heart Foundation
(number 89.063).
References
l Inman WHW, Vessey MP, Westerholm B, Engelund A.
Thromboembolic disease and the steroidal Content of oral
contraceptives: a report to the Committee on Safety of Drugs. BMJ
1970; ii: 203-09.
2 Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous
thromboembolismt Undings in a large prospective study. BMJ 1986;
292: 526.
3 Gerstmann BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV,
Lundin FE. Oral contraceptive estrogen dose and the risk of deep
venous thromboembolic disease. AmJEpidemiol 1991; 133: 32-37.
4 Böttiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives
and thromboembolic disease: effects of lowering oestrogen content.
Lancet 1980; i: 1097-101.
5 Robinson GE. Low-dose combined oral contraceptives. Br J Obstet
Gynaecol 1994; 101: 1036-42.
6 SperofT L, DeCherney A. Evaluation of a new generation of oral
contraceptives. Obstet Gynecol 1993; 81: 1034-47.
7 Fotherby K, Caldwell ADS. New progestogens in oral contraception.
Contraception 1994; 49: 1-33.
8 Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM,
Rosendaal FR. Increased risk of venous thrombosis in oral
contraceptive users who are carriers of factor V Leiden mutation.
Lancet 1994; 344: 1453-57.
9 Koster T, Rosendaal FR, Ronde H de, Briet E, Vandenbroucke JP,
Bertina RM. Venous thrombosis due to poor anticoagulant response to
activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342:
1503-06.
10 Bertina RM, Koeleman RPC, Koster T, et al. Mutation in blood
coagulation factor V associated with resistance to activated protein C.
Nature 1994; 369: 64-47.
11 Carter JC. The natural history and epidemiology of venous thrombosis.
Progr Cardiovasc Du 1994; 6: 423-38.
12 Janssen HF, Schachner MS, Hubbard J. The risk of deep venous
thrombosis: a computerized epidemiologic approach. Surgery 1987;
101: 205-12.
13 Lidegaard O. Oral contraception and risk of a cerebral thromboembolic
attack: results of a case-control study. BMJ 1993; 306: 956-63.
14 Shapiro S,. Rosenberg L, Slone D, Kaufman DW, Stolley PD,
Miettinen OS. Oral contraceptive use in relation to myocardial
infarction. Lancet 1979; i: 743^17.
Efficacy of traction for non-specific Iow back pain: a randomised
clinical trial
Anna J Beurskens, Henrica C de Vet, Albere J Koke, El ine Lindeman, Wiel Regtop, Geert J van der Heijden,
Paul G Knipschild
Summary
Previous trials to assess the efficacy of lumbar traction for
back pain have been methodologically flawed. To avoid
these shortcomings, we conducted a randomised
controlled trial in which high-dose traction was compared
with sham traction. The sham traction was given with a
specially developed brace that tightens in the back during
traction. To the patient, the experience is that of traction.
The patients and outcome assessor were blinded for the
assigned treatment.
151 patients with at least six weeks of non-specific Iow
back pain were randomised. Intention to treat analysis
showed no differences between the groups on all outcome
measures (patients' global perceived effect, severity of
main complaints, functional Status and pain); all 95%
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confidence intervals included the value zero. The number of
withdrawals from treatment, loss to follOv/-up, and protocol
deviations was Iow. Consequently, the per-protocol analysis
showed results similar to the Intention to treat analysis.
Subgroup analyses did not show any group for which
traction might seem promising.
Our data do not support the claim that traction is
effective for patients with Iow back pain.
Lancet 1995; 346: 1596-1600
Introduction
Each year 5% of the population in industrialised countries
experience an episode of Iow back pain (LBP)1·2 for which
there is no consensus about treatment. The efficacy of
mäny physiotherapeutic interventions is questionable.3"5
One of the treatment options is traction (motorised or
manual), which can be combined with other techniques,
such äs massage, exercises, electrotherapy, or heat.3
The supposed mechanical · effects of traction are
vertebral Separation and widening of the intervertebral
foramen.'-9 These mechanisms suggest short-term rather
than long-term effects or benefits.10·" Part of the applied
traction force is needed to overcome opposing forces,
namely friction of the body on the table-top, muscle
contraction, spinal curvatures, ligamentous resistance and
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